Medical Robotics
(Fourth Issue of 2025)
Industry News
Institute of Medical Robotics
To closely track the dynamics and trends of the medical robotics industry, the Institute of Medical Robotics at Shanghai Jiao Tong University began compiling medical robotics industry news in March 2021. Focusing on the development of the medical robotics industry against the backdrop of the national “Healthy China” strategic goal, the institute will closely monitor the dynamics of major ministries such as the National Medical Products Administration, the National Health Commission, and the Ministry of Science and Technology, as well as information from well-known companies in the industry, and filter this information to form news updates.
This issue introduces important financial investment dynamics in the medical robotics industry for July-August 2025. More exciting content from previous issues has been uploaded to the institute’s official website: https://imr.sjtu.edu.cn/cyzx.html, and everyone is welcome to download and read at any time~
03
Financial Investment
01
Orthopedic Giant Zimmer Biomet Acquires Fully Autonomous Surgical Robot Monogram Technologies for $1.2 Billion
On July 14, Zimmer Biomet announced the acquisition of Monogram Technologies for $177 million (approximately 1.2 billion RMB). This transaction marks an important strategic move for Zimmer Biomet in the field of orthopedic surgical robots, aiming to enhance the company’s technical capabilities in total knee arthroplasty (TKA) through Monogram’s innovative robotic systems and further improve the ecosystem of its Rosa robotic platform. The transaction is expected to be completed by the end of 2025.
Monogram Technologies, headquartered in Austin, Texas, focuses on developing advanced robotic-assisted surgical systems for orthopedic surgery. Since its inception, the company has concentrated on precise bone cutting and personalized implant solutions in orthopedic surgery, enhancing the accuracy and safety of joint replacement surgeries by integrating robotic operation, AI navigation, and 3D printing technology. Monogram’s core product, the mBôs system, is a semi-autonomous orthopedic surgical robot based on CT scans. This system received FDA 510(k) approval in March 2025 for total knee arthroplasty. With the integration of the mBôs system and the Rosa platform, future orthopedic surgeries may rely less on the experience of doctors and more on precise planning, intelligent guidance, and personalized implant solutions.
Semi-autonomous orthopedic surgical robot mBôs system
(Source: MedRobot)
★
02
US Medical Device Company NanoVibronix Reaches $50 Million Financing Agreement
On July 18, US-based NanoVibronix announced that it has reached a final agreement with an institutional investor to raise up to $50 million (approximately 360 million RMB) through a phased issuance of H-series convertible preferred shares. Recently, the company also officially announced the development plan for its next-generation bedside intelligent navigation robot platform ENvue Drive™, marking its transition from a manufacturer of acoustic therapy devices to a new phase of robotic-assisted intervention. According to the agreement, NanoVibronix will receive approximately $8.9 million in the first round of issuance, expected to close around July 21, 2025. The company will prioritize using $5 million of this to redeem outstanding X-series preferred shares, while the remaining funds will be directed towards the core module development, software and hardware engineering, and prototype validation of ENvue Drive.
ENvue Drive™ is an upgraded product of NanoVibronix’s ENvue platform, positioned as a bedside catheter implantation robot that combines electromagnetic navigation and AI intelligent path planning. The system is aimed at high-precision implantation operations such as feeding tubes and vascular access, addressing current issues in ICUs and NICUs that heavily rely on experience, consume nursing resources, and involve radiation exposure. NanoVibronix plans to accelerate the engineering and preclinical evaluation of ENvue Drive after the first round of financing is completed and to advance the FDA 510(k) pathway and early commercial demonstration site construction after additional financing is initiated.
(Source: MedRobot)
★
03
Endoscopic Surgical Robot Company Robotic Medical Completes Several Million Yuan Financing
On July 18, Shenzhen Robotic Medical Technology Co., Ltd. announced that it has completed several million yuan in strategic financing. This round of financing was led by Yuan Chang Fund under Fenglei Capital, with existing shareholder Taikun Fund participating. The financing has three main purposes: core technology iteration and product line expansion, accelerating the performance optimization and clinical implementation of the existing core product EndoFaster surgical robot, and advancing the research and development of the next-generation product “EndoDreams” surgical robot; capacity enhancement and supply chain optimization, representing a new era of technological revolution that is reconstructing the global economic landscape, with the entire industry chain related to new technology being rebuilt under the influence of new technological advancements; deepening clinical promotion, expanding clinical research cooperation with top hospitals, and accelerating product validation and popularization in the market.
(Source: ROBO Technology)
★
04
US Magnetic Navigation Surgical Robot Company Stereotaxis Completes $12.5 Million Financing
On July 18, robotic cardiac intervention technology company Stereotaxis announced the completion of approximately $12.5 million (about 89.7 million RMB) in a registered direct offering, selling common stock at a price of $2.00 per share. The financing was led by a strategic industry partner, with participation from some institutional investors. The first phase of approximately $8.5 million was completed around July 18, 2025, and the second phase of $4 million is expected to be completed by November 25, 2025. Lake Street Capital Markets LLC acted as the exclusive placement agent. The funds raised will be used to accelerate product commercialization, support R&D, and for other corporate purposes. Stereotaxis will use the proceeds to support its product line, including the Genesis RMN® cardiac electrophysiology robotic magnetic navigation system and ablation catheter technology.
Stereotaxis, founded in 2001 and headquartered in St. Louis, USA, is a globally recognized innovator in minimally invasive vascular robotic technology. The company is known for its proprietary Robotic Magnetic Navigation (RMN) platform, which enhances the precision of catheter tip movement to 0.1 mm through precise control of external magnetic fields, bringing higher safety and consistency to cardiac electrophysiology procedures. The company is committed to providing not only navigation platforms but also specialized catheters, imaging software, and future AI-assisted navigation algorithms, building a complete ecosystem for electrophysiological interventions.
(Source: RoboticTech)
END
Disclaimer: To comprehensively organize information related to the medical robotics industry, some images and texts are sourced from the internet. If there is any infringement, please contact us for removal.
Shanghai Jiao Tong University Institute of Medical Robotics
Scan the QR code to follow us~